Prurigo Nodularis

Latest News

Shawn Kwatra, MD, Endowed as Dr. Joseph Warren Burnett Professor of Dermatology at the University of Maryland School of Medicine

By Kaitlyn Bader, Assistant Managing Editor

April 16th 2025

Colleagues, mentors, and patients gathered to discuss Kwatra’s immense achievements throughout his career and the milestones that led to his endowed position.

Study Reports Efficacy of Tofacinitib in Itch, Skin Infiltration Reduction for Prurigo Nodularis

By Emma Andrus, Editor

April 7th 2025

Unraveling Type 2 Inflammation in Skin Diseases

By Maddi Hebebrand, MC, Associate Editor

March 26th 2025

Breakthrough Therapies in Itch Management: Insights From Brian S. Kim, MD, FAAD

By Brian Kim, MD
Heidi Anne Duerr, MPH

March 10th 2025

Real-World Data Supports Dupilumab for Prurigo Nodularis Treatment in China

By Marie Bosslett, Assistant Editor

January 29th 2025

More News

Late-Breaking Data: Long-Term Safety and Efficacy of Largest Prurigo Nodularis Study Ever Conducted

Kaitlyn Bader, Senior Editor ;Shawn Kwatra, MD, FAAD

March 11th 2024

Shawn Kwatra, MD, presented late-breaking data at AAD 2024 on the largest prurigo nodularis and nemolizumab clinical trial, OLYMPIA.

FDA Accepts Galderma’s BLA for Nemolizumab for the Treatment of Prurigo Nodularis and Atopic Dermatitis

Kaitlyn Bader, Senior Editor

February 14th 2024

The FDA has also granted nemolizumab Priority Review for prurigo nodularis.

Cryosim-1 Safe, Effective in Patients With Prurigo Nodularis

Emma Andrus, Associate Editor

January 9th 2024

A randomized, placebo-controlled trial of the selective transient receptor potential melastatin 8 agonist explored its efficacy and safety in PN.

<1 2

About

Advertise

Job Board

Do Not Sell My Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777